194 related articles for article (PubMed ID: 1555257)
21. Effect of interleukin-1 alpha on the in vitro activation of tumor-draining lymph node cells for adoptive immunotherapy.
Hammel JM; Tuck MK; Hain JM; Chang AE; Sondak VK
J Immunother Emphasis Tumor Immunol; 1994 Jul; 16(1):1-12. PubMed ID: 8081555
[TBL] [Abstract][Full Text] [Related]
22. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
23. IL-10: a novel cytotoxic T cell differentiation factor.
Chen WF; Zlotnik A
J Immunol; 1991 Jul; 147(2):528-34. PubMed ID: 1906502
[TBL] [Abstract][Full Text] [Related]
24. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
Colquhoun SD; Economou JS; Shau H; Golub SH
J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
[TBL] [Abstract][Full Text] [Related]
25. IL-7 supports the generation of cytotoxic T lymphocytes from thymocytes. Multiple lymphokines required for proliferation and cytotoxicity.
Bertagnolli M; Herrmann S
J Immunol; 1990 Sep; 145(6):1706-12. PubMed ID: 2118152
[TBL] [Abstract][Full Text] [Related]
26. Phenotypic and functional heterogeneity of thymic and splenic lymphokine activated killer cells relative to ornithine sensitivity.
Mehrotra P; Bear HD; Susskind BM
Cell Immunol; 1991 Feb; 132(2):451-65. PubMed ID: 1899052
[TBL] [Abstract][Full Text] [Related]
27. IL-4 regulation of a protein kinase C independent pathway for the generation of alpha CD3-induced activated killer cells.
Ting CC; Hargrove ME
Cell Immunol; 1992 Mar; 140(1):130-44. PubMed ID: 1531452
[TBL] [Abstract][Full Text] [Related]
28. In vivo evaluation of the effects of interleukins 2, 4 and 7 on enhancing the immunotherapeutic efficacy of anti-tumor cytotoxic T lymphocytes.
Lynch DH; Namen AE; Miller RE
Eur J Immunol; 1991 Dec; 21(12):2977-85. PubMed ID: 1684156
[TBL] [Abstract][Full Text] [Related]
29. OK-432 develops CTL and LAK activity in mononuclear cells from regional lymph nodes of lung cancer patients.
Takahashi K; Harauchi D; Kimura S; Saito S; Monden Y
Int J Immunopharmacol; 1998 Aug; 20(8):375-88. PubMed ID: 9778099
[TBL] [Abstract][Full Text] [Related]
30. Differential sensitivity of cytotoxic T lymphocytes and lymphokine-activated killer cells to inhibition by L-ornithine.
Susskind BM; Sekar J; Tandon PM; Lind DS; Bear HD
Cell Immunol; 1991 Mar; 133(1):41-54. PubMed ID: 1899361
[TBL] [Abstract][Full Text] [Related]
31. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
[TBL] [Abstract][Full Text] [Related]
32. Human cytotoxic CD8+ T-lymphocyte clones engraft in severe combined immunodeficient (SCID) mice but show diminished function.
de Kroon JF; van Bergen CA; de Paus RA; Kluin-Nelemans HC; Willemze R; Falkenburg JH
J Immunother; 1997 Mar; 20(2):101-10. PubMed ID: 9087382
[TBL] [Abstract][Full Text] [Related]
33. In vitro expansion of tumor-specific, HLA-restricted human CD8+ cytolytic T lymphocytes.
Nakashima M; Watanabe T; Koprowski H; Schuchter L; Steplewski Z
Cell Immunol; 1994 Apr; 155(1):53-61. PubMed ID: 7513262
[TBL] [Abstract][Full Text] [Related]
34. Regulation of cytolytic T-lymphocyte generation by B-cell stimulatory factor.
Widmer MB; Grabstein KH
Nature; 1987 Apr 23-29; 326(6115):795-8. PubMed ID: 3494950
[TBL] [Abstract][Full Text] [Related]
35. Requirements for activation of CD8+ murine T cells. I. Development of cytolytic activity.
Cronin DC; Lancki DW; Fitch FW
Immunol Res; 1994; 13(4):215-33. PubMed ID: 7616050
[TBL] [Abstract][Full Text] [Related]
36. Induction of murine lymphokine-activated killer cells by recombinant IL-7.
Lynch DH; Miller RE
J Immunol; 1990 Sep; 145(6):1983-90. PubMed ID: 1975262
[TBL] [Abstract][Full Text] [Related]
37. TGF-beta mediates natural suppressor activity of IL-2-activated lymphocytes.
Yamamoto H; Hirayama M; Genyea C; Kaplan J
J Immunol; 1994 Apr; 152(8):3842-7. PubMed ID: 8144953
[TBL] [Abstract][Full Text] [Related]
38. Synergy between recombinant interleukin 2 (rIL 2) and IL 2-depleted lymphokine-containing supernatants in facilitating allogeneic human cytolytic T lymphocyte responses in vitro.
Gately MK; Wilson DE; Wong HL
J Immunol; 1986 Feb; 136(4):1274-82. PubMed ID: 2418110
[TBL] [Abstract][Full Text] [Related]
39. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
Yoshizawa H; Chang AE; Shu S
J Immunol; 1991 Jul; 147(2):729-37. PubMed ID: 1830072
[TBL] [Abstract][Full Text] [Related]
40. Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism.
Gamero AM; Ussery D; Reintgen DS; Puleo CA; Djeu JY
Cancer Res; 1995 Nov; 55(21):4988-94. PubMed ID: 7585540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
